Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes: Whitehall II Prospective Cohort Study

OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectorie...

Descripción completa

Detalles Bibliográficos
Autores principales: Carstensen, Maren, Herder, Christian, Kivimäki, Mika, Jokela, Markus, Roden, Michael, Shipley, Martin J., Witte, Daniel R., Brunner, Eric J., Tabák, Adam G.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857902/
https://www.ncbi.nlm.nih.gov/pubmed/20185814
http://dx.doi.org/10.2337/db09-1199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857902/
https://www.ncbi.nlm.nih.gov/pubmed/20185814
http://dx.doi.org/10.2337/db09-1199

Ejemplares similares